Oral Obesity Candidates Disappoint With Novo Emerging as Leader of the Pack
With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” investors, William Blair’s Andy Hsieh predicts weight loss pills will play a bigger role in low- and middle-income countries than in the U.S.Read more:
biospace.comBiotechnology